Goldman Sachs Sticks to Its Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)
Goldman Sachs analyst Davinthra Thillainathan maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – Research Report) on May 20 and set a price target of A$49.30. The company’s shares closed today at A$38.24.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Thillainathan covers the Healthcare sector, focusing on stocks such as Ramsay Health Care, CSL, and Cochlear . According to TipRanks, Thillainathan has an average return of 3.7% and a 75.00% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh with a A$44.69 average price target.
RMD market cap is currently A$56.58B and has a P/E ratio of 27.15.
Read More on AU:RMD:
Disclaimer & DisclosureReport an Issue
- Morgan Stanley sees ‘modest’ earnings impact to ResMed from Apnimed
- Apnimed data brings competitive threat to ResMed, says RBC Capital
- Resmed’s Growth Potential Highlighted by Promising Trial Results and Future Opportunities
- Buy Rating for Resmed: Positive Phase 3 Trial Results and Market Conditions Boost AD109’s Appeal
- ResMed named Sleep Partner of the Qatar Airways British & Irish Lions Tour
